Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's [PMID: 41183609] Laboratory literature summary: FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide
Research suggests many people regain around two-thirds of the weight they lost within a year of stopping
At Huemn, Dihexa is used in personalized cognitive optimization programs to enhance neural connectivity, protect against decline, and promote mental clarity
As of June this year, the drug recorded a moving annual turnover (MAT) of Rs 130 crore and has so far managed to retain its market share, leveraging aggressive discounts up to 50 per cent , according to PharmaTrac estimates
( 2 in patients treated for advanced breast cancer (in combination with 5-fluorouracil and cyclophosphamide)
US$ 21.48
US$ 27.53
US$ 28.07
US$ 23.68
US$ 26.17
US$ 22.75
